J&J Says It Will Continue To Make Acquisitions; Med-Tech Biz Shines In Q4
This article was originally published in The Gray Sheet
Executive Summary
Johnson & Johnson says it will continue to invest in acquisitions following yet another strong quarter of medical device sales that salvaged its stagnant pharmaceutical business
You may also be interested in...
J&J To Focus On Small-To-Medium Size Acquisitions For The Time Being
J&J is targeting more small-to-medium size companies for acquisition now that ICD-maker Guidant is out of reach
J&J To Focus On Small-To-Medium Size Acquisitions For The Time Being
J&J is targeting more small-to-medium size companies for acquisition now that ICD-maker Guidant is out of reach
Cypher Shines At Taxus’ Expense: J&J Captures 46% Of U.S. Market
Johnson & Johnson/Cordis plans to increase its manufacturing capacity to be able to supply three-quarters of the U.S. drug-eluting stent market with Cypher by June 2006